|
RAB9A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
1.11269999880648E-08 |
| Normal-vs-Stage3 |
5.01820807130571E-14 |
| Normal-vs-Stage4 |
8.02469202199063E-12 |
| Stage1-vs-Stage2 |
4.769800E-01 |
| Stage1-vs-Stage3 |
1.055640E-01 |
| Stage1-vs-Stage4 |
8.313500E-02 |
| Stage2-vs-Stage3 |
8.014800E-01 |
| Stage2-vs-Stage4 |
5.962200E-01 |
| Stage3-vs-Stage4 |
6.881800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.00329999999749E-05 |
| Normal-vs-Asian |
2.27849999978602E-08 |
| Caucasian-vs-AfricanAmerican |
5.456800E-01 |
| Caucasian-vs-Asian |
2.786600E-01 |
| AfricanAmerican-vs-Asian |
8.685600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
1.431840E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.98718819177657E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-15 |
| Normal-vs-Age(61-80Yrs) |
2.83673085021974E-12 |
| Normal-vs-Age(81-100Yrs) |
3.822500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.505800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.331800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.115400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.257000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.906400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.290200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.114000E-01 |
| Classical-VS-Follicular |
1.023610E-01 |
| Classical-VS-Other |
4.542600E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
6.459000E-01 |
| Tall-VS-Other |
8.061000E-01 |
| Tall-VS-Normal |
5.43520006779374E-10 |
| Follicular-VS-Other |
9.490200E-01 |
| Follicular-VS-Normal |
1.87200255297171E-11 |
| Other-VS-Normal |
6.971700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.5527136788005E-15 |
| Normal-vs-N1 |
3.60911300845146E-12 |
| N0-vs-N1 |
1.260150E-01 |
|
|
